CONSORT diagram. All patients within BioVU were screened via ICD or text phrase for myelofibrosis. Patients identified were then prioritized via a screening algorithm and confirmed myelofibrosis via manual review conforming to WHO 2016 guidelines. The final cohort after meeting strict Inclusion criteria were then sequenced via NGS and had risk score recapitulation performed.